KRX Bio Technology Transfer Index

Top-line results from the U.S. Phase 3 clinical trial of TG-C (formerly Invossa), a treatment for knee osteoarthritis, are expected in July 2026. This is a critical catalyst given the drug's past license cancellation. Date is an estimate for the end of the expected month expected

Announced Q1 2026 earnings with net profit doubling to 20.8 billion KRW year-over-year, largely due to a 19 billion KRW one-time reversal of provisions for lawsuits. Operating profit also improved to 2.9 billion KRW.

Hanmi Pharm announced the first patient dosing in a domestic Phase 3 clinical trial for 'Efpeglenatide' on 2026-05-18. The stock price fell approximately 8% on the day of the announcement.

Announced Q1 2026 earnings on 2026-05-18, reporting an operating loss of 42.2 billion KRW, a significant shift from a profit in the previous year, primarily due to a 125.7% increase in R&D expenses.

The U.S. Patent Trial and Appeal Board (PTAB) rejected Halozyme Therapeutics' petition to review Alteogen's ALT-B4 patent on May 15, 2026. This legal victory strengthens patent protection and AI estimates a high price impact (≥10%) expected.

ABL Bio announced that its partner Ionis Pharmaceuticals presented positive preclinical results for the 'Grabody-B' BBB shuttle platform at the TIDES USA 2026 conference on May 13, 2026, showing effective delivery of siRNA to major brain regions.

Announced on May 15, 2026, that its P-CAB drug Fexuclue (Fexuprazan) received an additional indication approval from the Korean MFDS for the eradication of H. pylori.

OliX Pharmaceuticals is expected to file its Q1 2026 report on May 15, 2026, showing revenue of 3.6 billion KRW and an operating loss of 10.8 billion KRW. Low importance is estimated as the financial results are expected to be within the typical range for a biotech firm. expected

Yuhan announced on 2026-05-14 it will receive a USD 30 million (approx. KRW 44.9 billion) milestone payment from Janssen for the European commercialization of its lung cancer drug, Leclaza. The stock price rose 5.43% on the day of the announcement.

Q1 2026 earnings announcement reporting a turnaround to an operating profit of 137 million KRW and net profit of 1.146 billion KRW; >5% price impact estimated due to return to profitability, expected.

Received Investigational New Drug (IND) approval from the U.S. FDA for 'LCB02A' on 2026-05-14 to initiate Phase 1/2 clinical trials for advanced solid tumors.

Received marketing approval from South Korea's Ministry of Food and Drug Safety for 'Aijen' (ALT-L9) on May 14, 2026. This product approval is estimated to have a medium price impact (≥5%) by AI expected.

1st quarter 2026 earnings report released on 2026-05-14. The company reported continued operating losses as R&D expenses increased, with no new revenue from technology transfers during the period. Medium importance assigned as quarterly earnings typically impact market sentiment.

CEO Dong Ki Lee is scheduled to present the company's eye disease treatment strategy and RNAi platform research at the TIDES USA 2026 conference on May 14, 2026. Low importance is estimated as conference presentations typically have limited immediate price impact. scheduled